FDA Approves Cymbalta(R) For The Management Of Fibromyalgia

The U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder, Eli Lilly and Company (NYSE: LLY) announced. Cymbalta is the first serotonin- norepinephrine reuptake inhibitor with proven efficacy for reducing pain in patients with fibromyalgia.

More: continued here

Filed under: Pain / Anesthetics on June 19th, 2008